Lisata Therapeutics, Inc. announced treatment of the first patient in a Phase 2a trial evaluating LSTA1 in patients with newly diagnosed glioblastoma multiforme (?GBM?). The trial is an investigator-initiated study by Lenne-Triin Kõrgvee, MD, PhD, principal investigator of the study. The first patient was enrolled at Tartu University Hospital in Tartu, Estonia.

The study is a Phase 2a, double-blind, placebo-controlled, randomized, proof-of-concept study evaluating LSTA1 when added to standard of care, temozolomide, versus SoC and placebo in subjects with newly diagnosed GBM. The study is being conducted across multiple sites in Estonia and Latvia and is targeted to enroll 30 patients with a randomization of 2:1 in favor of the LSTA1 treatment group. In addition to provisioning LSTA1, Lisata will also provide funding for this study.

As previously announced by the Company, LSTA1 has been granted orphan drug designation by the U.S. FDA for malignant glioma.